Are Pharmaceuticals Poised for a Rebound? The Key Metric to Keep in Mind With pharmaceutical M&A ramping up and robust pipelines with high impact launches on the horizon, investors may be considering renewed exposure to this subset of Health Care stocks. However, those focused on free cash flow (FCF) metrics may have already identified opportunities in the sector. VictoryShares Free Cash Flow ETF (VFLO)currently offers exposure to this area of the market that could be worth consideration. VFLO's top holding ...

Merck & Co., Inc. (NYSE:MRK) is one of the best affordable stocks to buy with good earnings growth. Merck & Co., Inc. (NYSE:MRK) and Terns Pharmaceuticals, Inc. announced on March 25 their entry into a definitive agreement under which Merck, through a subsidiary, will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion. Management stated that this translates to around $5.7 billion net of acquired cash, representing an approximate premium of 31% to the 60-day and 42% t ...

Financial Data and Key Metrics Changes - The net loss for the year ended December 31, 2025, was approximately $34.5 million or $0.74 per basic and diluted share, compared to a net loss of $37.6 million or $1.03 per basic and diluted share for the year ended December 31, 2024, indicating an improvement in financial performance [15] - Research and development expenses for the year ended December 31, 2025, were $19 million, down from $22.6 million in 2024, primarily due to decreases in manufacturing and personnel costs [15] - General and administrative expenses decreased to $12.5 million in 2025 from $13.8 million in 2024, reflecting a reduction in personnel costs [16] Business Line Data and Key Metrics Changes - The company reported encouraging early results from the PDS-01ADC trial, showing a median progression-free survival (PFS) of 9.6 months and a 40% median decline in prostate-specific antigen (PSA) levels in patients with metastatic castration-resistant prostate cancer [5][6] - The VERSATILE-002 trial demonstrated a median overall survival of 39.3 months for patients with HPV-16 positive head and neck cancer, marking a significant clinical achievement [9] Market Data and Key Metrics Changes - The company highlighted the growing unmet need for treatments in HPV-16 positive cancers, which are rapidly increasing in the U.S. and EU due to low vaccination rates [12] - The amendment to the VERSATILE-003 trial protocol aims to accelerate the availability of PDS0101 to the growing population of HPV-16 positive patients [11] Company Strategy and Development Direction - The company is focused on advancing PDS0101 as a promising treatment option for HPV-16 positive head and neck cancer, with a strategic amendment to the VERSATILE-003 trial to include PFS as a primary endpoint [4][10] - The company has strengthened its intellectual property portfolio with new patents granted in the U.S. and Japan, extending market protection into the 2040s [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of PDS0101 to provide a well-tolerated treatment option without chemotherapy for HPV-16 positive patients, who currently lack effective therapies [14] - The company anticipates meaningful opportunities ahead as it continues to execute its priorities in 2026, particularly with the early data from the PDS-01ADC program [38] Other Important Information - The company emphasized the convenience of PDS0101 as a subcutaneous injection requiring only five doses, compared to over twenty doses for most therapeutic approaches [12] Q&A Session Summary Question: What will the revised enrollment target look like for the amended protocol? - The trial duration has been shortened to about a year for final results, with the interim analysis for PFS expected in approximately a year and a half [20] Question: How should R&D expenses be expected for 2026 with the smaller trial design? - While specific financial guidance was not provided, R&D costs are expected to increase once the trial is reinitiated, commensurate with site openings and patient enrollment [23] Question: How will patients already enrolled prior to the VERSATILE-003 pause be handled? - Patients who started on the trial will continue their treatment as indicated by the protocol, and they will be included in a special subset of the data for safety [27] Question: What is the expected enrollment pace based on last year's execution? - The enrollment pace is expected to be robust due to positive responses from sites and less competition compared to when the trial first began [29] Question: Can you share the powering assumptions for the interim PFS and the new sample size for the phase III? - The sample size has not been made public yet, but the PFS is powered to detect statistically significant changes, with two interim analyses planned [34]

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is one of the popular penny stocks on Robinhood to buy. On March 23, Piper Sandler analyst Joseph Catanzaro raised his price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $12 from $10, while maintaining an Overweight rating. This move followed encouraging Phase 1 clinical data from CytomX’s lead drug candidate, varsetatug maseatecan, or varseta-M. CytomX Therapeutics (CTXM) Gains Analyst Confidence on Trial Progress Pixabay/Public domain Catanzaro noted tha ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Immutep Limited following a significant decline in stock price after the discontinuation of a clinical trial [1][3][4]. Group 1: Investigation Details - The investigation focuses on whether Immutep's executive officers may have violated federal securities laws, leading to investor losses [1][4]. - The Independent Data Monitoring Committee recommended discontinuation of Immutep's Phase III TACTI-004 clinical trial due to an interim futility analysis indicating the trial was unlikely to meet its primary endpoints [3]. Group 2: Stock Performance - Following the announcement of the trial discontinuation, Immutep's stock price plummeted approximately 85–90% in a single trading session [4]. Group 3: Legal Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and has recovered approximately $90,725,000 for clients in securities class action lawsuits [5][6].

Core Insights - Merck & Co., Inc. is implementing strategic initiatives to address the impending loss of exclusivity for its key drug, KEYTRUDA, anticipating only a shallow revenue dip as a result [1] Group 1: Strategic Initiatives - The company is focusing on innovation to enhance its product portfolio through the introduction of new products [2] - Merck is expanding its oncology pipeline and exploring new treatment options in cardiovascular and other therapeutic areas [2] - Upcoming product launches include WINREVAIR, OHTUVAYRE, CAPVAXIVE, INFLUENZA, and QULEX [2] Group 2: Clinical Developments - Ongoing clinical trials for MK-1406, aimed at influenza prevention, are taking place in the Southern Hemisphere [3] - The neoantigen therapy V940 is under development, with a melanoma readout expected in 2028 [3] - MK-3000 is being developed to target patients with diabetic macular edema and neovascular AMD [3] Group 3: Growth Opportunities - Merck is developing over 20 new growth drivers in its human health business, targeting a commercial opportunity of $70 billion [4] - The company aims to double its animal health revenue by mid-2030 through strategic business development [4] Group 4: Company Overview - Merck & Co., Inc. is a leading global biopharmaceutical company focused on discovering, developing, and manufacturing prescription medicines, vaccines, and biologic therapies [5] - The company specializes in human health, particularly in oncology, infectious diseases, and immunology, while also providing animal health products [5]

Core Viewpoint - Wells Fargo has raised its price target for Merck (MRK) to $150, driven by the potential of sacituzumab tirumotecan (sac-TMT) to replace chemotherapy in various cancer treatments, alongside the growth of KEYTRUDA and a robust pipeline of 80 Phase 3 studies [1] Group 1: Stock Performance and Predictions - Merck's stock has gained 23% over the past year and 8% year-to-date, currently trading below its 52-week high of $125.14 [1] - The Street consensus price target for Merck is $127.22, while Wells Fargo's target of $150 suggests significant upside potential [1] - Achieving a $150 price target would imply a market capitalization exceeding $283.4 billion, necessitating positive late-stage data for sac-TMT and sustained growth for KEYTRUDA [1] Group 2: Key Drivers of Stock Performance - Emerging growth portfolio: WINREVAIR, Merck's treatment for pulmonary arterial hypertension, generated $467 million in Q4 2025, reflecting a 133% year-over-year increase [1] - KEYTRUDA's revenue reached $8.337 billion in Q4 2025, up 6% year-over-year, with new FDA approvals expanding its indications [1] - The potential of sac-TMT to displace chemotherapy in multiple cancer types represents a significant commercial opportunity for Merck's oncology franchise [1] Group 3: Strategic Developments - The FDA awarded sac-TMT a Commissioner's National Priority Voucher, indicating strong regulatory support for its development [1] - A strategic financing agreement with Blackstone Life Sciences has been established to partially fund the development of sac-TMT [1]

Summary of Amgen Conference Call Company Overview - **Company**: Amgen - **Key Participants**: Peter Griffith (CFO), Jasper van Grunsven (SVP of Rare Disease), Casey Capparelli (VP of Investor Relations) [8][1] Core Industry Insights - **Strong Portfolio Performance**: In 2025, Amgen reported strong momentum with 13 products delivering double-digit growth, 14 products exceeding $1 billion in annual sales, and 18 products achieving record performance [8][9] - **Key Growth Drivers**: The growth is supported by six key drivers: Repatha, Evenity, Tezspire, rare disease portfolio, innovative oncology, and biosimilars [8][9] - **Rare Disease Portfolio**: Generated $5 billion in sales in 2025, up 14% year-over-year, with significant contributions from UPLIZNA, which grew 73% due to new indications and geographic expansion [9][31] Financial Highlights - **Revenue and Earnings Growth**: Amgen experienced double-digit growth in both revenue and earnings per share in 2025 [8][9] - **Biosimilars Performance**: The biosimilars portfolio generated $3 billion in sales in 2025, growing 37% year-over-year, driven by strong uptake of Pavblu [11][20] - **Quarterly Expectations**: Anticipated seasonal headwinds in Q1 due to insurance cycles and historical sales patterns, particularly for Otezla and IMRALDI [14][15] Product-Specific Insights - **UPLIZNA**: Expected to continue strong growth with a focus on new indications and a competitive profile in the market [31][36] - **MariTide**: Positioned as a differentiated treatment for obesity and related conditions, with six global Phase III studies underway. Monthly dosing is expected to improve patient adherence [12][25][62] - **IMDELLTRA**: A bispecific T-cell engager for small cell lung cancer, rapidly becoming the standard of care with ongoing Phase III studies [10][19] Pipeline and Future Growth - **Pipeline Development**: 2026 is set to be a year of disciplined data generation across multiple Phase II and III programs, with a focus on long-term growth [12][20] - **Dazodalibep (DAS)**: Targeting Sjögren's disease, with a significant unmet need and promising Phase II data [50][51] Competitive Landscape - **Market Positioning**: Amgen is aware of competitive pressures, particularly in the obesity market from companies like Lilly and Novo, but believes its established commercial capabilities will provide a competitive edge [68][69] - **M&A Environment**: Amgen maintains a strong balance sheet and is open to M&A opportunities, focusing on innovation and integration capabilities [70][72] Additional Considerations - **Adherence and Patient Experience**: Emphasis on improving patient adherence through less frequent dosing regimens, which is crucial for chronic conditions [62][63] - **Commercial Strategy**: Amgen is strategizing on how to effectively position MariTide in a rapidly evolving market, considering both commercial and consumer segments [58][59]

Merck & Co (NYSE:MRK) FY Conference Summary Company Overview - **Company**: Merck & Co - **Event**: Sixth Annual Healthcare Conference - **Date**: March 03, 2026 - **Key Speakers**: Caroline Litchfield (CFO), Dr. Dean Li (President of Merck Research Laboratories) Key Points Industry and Company Transformation - Merck is transforming its portfolio with the launch of several new products including WINREVAIR, OHTUVAYRE, CAPVAXIVE, INFLUENZA, and QULEX, aiming for over 20 new growth drivers in human health [2][3] - The company anticipates a commercial opportunity exceeding $70 billion from these products [2] - The animal health business is expected to double its revenues by the mid-2030s [2] Pipeline and Product Development - Merck has a robust early-stage pipeline with six late-stage pipeline readouts expected in 2026 and 2027 [4] - Key products in the pipeline include: - **sac-TMT** and **I-DXd**: Important for cancer treatment, with ongoing trials [7][17] - **MK-3000**: A new mechanism for treating diabetic macular edema and neovascular AMD, targeting patients who do not respond to existing treatments [10][11] - **Islatravir**: A once-weekly oral treatment for HIV, showing over 90% adherence and efficacy in trials [14] - **SAC-TMT**: Differentiated from existing Trop-2 ADCs, with promising data from trials in lung and breast cancer [15][17] Market Dynamics and Competitive Landscape - Merck is confident in navigating the loss of exclusivity for KEYTRUDA, expecting a shallow revenue dip followed by strong growth [3] - The company is focusing on the oral PCSK9 therapy, which is anticipated to catalyze market growth due to guideline changes [25][26] - Merck's inclisiran is expected to launch in Q1 2027, with strong clinical data supporting its efficacy [30] Future Outlook - Merck aims to diversify its product offerings beyond KEYTRUDA, Gardasil, and Animal Health, focusing on first-in-class and best-in-class innovations [61] - The company is committed to driving growth and delivering returns for shareholders through its evolving product portfolio [61] Other Notable Mentions - **Gardasil**: Expected to maintain stable revenues in 2026, with a focus on the mid-adult segment [57] - **MK-1406**: An antiviral conjugate for influenza, targeting immunocompromised patients, with a significant market opportunity [20] - **Nemtabrutinib**: A competitive entry in the CLL market, with a focus on diversifying oncology offerings [48] Conclusion Merck is positioned for significant growth through its diverse pipeline and strategic product launches, with a strong emphasis on innovation and market adaptation. The company is optimistic about its future, aiming to transform its business model and enhance shareholder value.

Summary of Corbus Pharmaceuticals FY Conference Call Company Overview - **Company**: Corbus Pharmaceuticals (NasdaqCM:CRBP) - **Location**: Norwood, Massachusetts - **Size**: 36 employees - **Pipeline**: Focus on oncology with lead asset CRB-701 (Nectin-4 ADC) and obesity with CRB-913 (CB1 inverse agonist) [4][5] Key Points on CRB-701 (Nectin-4 ADC) - **Mechanism**: CRB-701 is a Nectin-4 targeting ADC armed with MMAE, designed to have better internalization and stability compared to PADCEV [6][9] - **Differentiation**: CRB-701 targets a different epitope and has a precise drug-to-antibody ratio (DAR) of 2, leading to lower levels of circulating MMAE and reduced side effects [7][10] - **Safety Profile**: Notable for low levels of peripheral neuropathy and skin issues, but potential ocular toxicity is acknowledged [15][16] - **Clinical Data**: Preliminary efficacy signals observed in second-line head and neck and cervical cancers, with expectations for more mature data in mid-2026 [30][31] - **Market Strategy**: Focus on tumor types where PADCEV is not a competitor, aiming for "empty swim lanes" in the competitive landscape [11] Key Points on CRB-913 (CB1 Inverse Agonist) - **Mechanism**: CRB-913 is a peripherally restricted CB1 inverse agonist, expected to lead to weight loss with a favorable safety profile [65][66] - **Efficacy Data**: Early data shows significant weight loss (almost 3% at 2 weeks) across all patients, with ongoing studies to assess longer-term effects [66][67] - **Safety Profile**: Minimal neuropsychiatric adverse events reported, indicating a favorable safety profile compared to previous CB1 antagonists [68][69] - **Market Potential**: Positioned to compete in the obesity market, with expectations for transformative data by the end of summer 2026 [70][75] Other Important Insights - **Tivdak Comparison**: CRB-701 is positioned to potentially replace Tivdak in the cervical cancer market, which had $300 million in sales despite its high cost and limited patient eligibility [32][33] - **Regulatory Pathway**: Plans for FDA discussions regarding phase 3 trials for both CRB-701 and CRB-913, with updates expected in Q1 2026 [55][56] - **Market Dynamics**: The oncology market is competitive, with a focus on differentiating CRB-701 from existing therapies like Genmab's peto and exploring combination therapies with KEYTRUDA [49][50] This summary encapsulates the key points discussed during the conference call, highlighting the strategic direction and clinical developments of Corbus Pharmaceuticals.